OX40/TNFRSF4 Antibody (2553B) [Unconjugated]

Human peripheral blood mononuclear cells (PBMCs) were treated with 5 μg/ml PHA for 5 days then stained with Mouse Anti-Human CD3 epsilon PE-conjugated Monoclonal Antibody FAB100P) and either (A) Rabbit Anti-Human OX40/TNFRSF4 Monoclonal Antibody (Catalog # MAB10545) or (B) Rabbit IgG Isotype Control (MAB1050) followed by APC-conjugated Anti-Rabbit IgG Secondary Antibody F0111). View our protocol for Staining Membrane-associated Proteins.

• Reactivity: Hu
• Applications: Flow, CyTOF-ready
• Clone: 2553B
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated

OX40/TNFRSF4 Antibody (2553B) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Mouse myeloma cell line NS0-derived recombinant human OX40/TNFRSF4
  Leu29-Ala216
  Accession # P43489
• Specificity: Detects human OX40/TNFRSF4 in direct ELISAs.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
  *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for OX40/TNFRSF4 Antibody (2553B) [Unconjugated]

• ACT-135
• ACT35 antigen
• ACT35ATC35 antigen
• CD134 antigen
• CD134
• Ly-70
• OX40 cell surface antigen
• OX40 homologue
• OX40
• OX40L receptor
• OX40lymphoid activation antigene ACT35
• TAX transcriptionally-activated glycoprotein 1 receptor
• tax-transcriptionally activated glycoprotein 1 receptor
• TNFRSF4
• tumor necrosis factor receptor superfamily member 4
• tumor necrosis factor receptor superfamily, member 4
• Txgp1
• TXGP1L
• TXGP1LOX40 antigen

Background

OX40 (CD134; TNFRSF4) is a T cell co-stimulatory molecule of the TNF receptor superfamily that coordinates with other co-stimulators (CD28, CD40, CD30, CD27 and 4-1BB) to manage the activation of the immune response (1-3). Human OX40 is a 48 kDa type I transmembrane glycoprotein with a 28 amino acid (aa) signal sequence, a 185 aa extracellular domain (ECD) that contains a cysteine-rich region, a 20 aa transmembrane segment, and a 41 aa cytoplasmic domain (4). The ECD of human OX40 shares 63% sequence identity with the ECD of mouse and rat OX40. OX40 is up-regulated on CD4⁺ and CD8⁺ T cells upon engagement of the TCR by antigen presenting cells along with co-stimulation by CD40-CD40 Ligand and CD28-B7 (5, 6). OX40 Ligand is primarily expressed on antigen presenting cells (5). OX40 Ligand engagement of OX40 on activated CD4⁺ T cells results in increased T cell survival, proliferation, and cytokine production. It also inhibits the conversion of effector T cells into immunosuppressive regulatory T cells (Tregs) and can promote the maintenance of and recall response in memory T cells (3, 7-10). OX40 is constitutively expressed on Tregs and enhances the sensitivity of Tregs to IL-2, thus promoting Treg proliferation. OX40 has also been shown to decrease the cells’ immunosuppressive activity on effector T cells (11-14). OX40-OX40 Ligand signaling is involved in allergic airway inflammation, graft-versus-host disease and autoimmune disease (6, 15, 16). Mutations in OX40 and OX40 Ligand are associated with cardiovascular disease (17, 18).

1. Hori, T. (2006) Int. J. Hematol. 83:17.
2. Latza, U. et al. (1994) Eur. J. Immunol. 24:677.
3. Salek-Ardakani, S. et al. (2003) J. Exp. Med. 198:315.
4. al-Shamkhani, A. et al. (1996) Eur. J. Immunol. 26:1695.
5. Moran, A.E. et al. (2013) Curr. Opin. Immunol. 25:230.
6. Gramaglia, I. et al. (1998) J. Immunol. 161:6510.
7. Xiao, X. et al. (2008) J. Immunol. 181:3193.
8. So, T. and M. Croft (2007) J. Immunol. 179:1427.
9. Mousavi, S.F. et al. (2008) J. Immunol. 181:5990.
10. Bansal-Pakala, P. et al. (2001) Nat. Med. 7:907.
11. Piconese, S. et al. (2010) Eur. J. Immunol. 40:2902.
12. Griseri, T. et al. (2010) J. Exp. Med. 207:699.
13. Xiao, X. et al. (2012) J. Immunol. 188:892.
14. Vu, M.D. et al. (2007) Blood 110:2501.
15. Damayanti, T. et al. (2010) Am. J. Respir. Crit. Care Med. 181:688.
16. Xiao, X. et al. (2012) Nat. Immunol. 13:981.
17. Nakano, M. et al. (2010) Cardiovasc. Res. 88:539.
18. Ishii, N. et al. (2010) Adv. Immunol. 105:63.
19. Godfrey, W.R. et al. (1994) J. Exp. Med. 180:757

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P43489()